H.C. Wainwright raised the firm’s price target on Travere Therapeutics to $20 from $18 and keeps a Buy rating on the shares after the company announced it opened enrollment in the HARMONY study, a pivotal Phase 3 clinical trial of pegtibatinase for the treatment of classical homocystinuria. The analyst believes the Street undervalues the company’s pegtibatinase program. The firm continues to believe pegtibatinase has the potential to become the first disease-modifying treatment for homocystinuria.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
- Travere Therapeutics initiates Phase 3 trial of pegtibatinase
- Citi upgrades Travere to Buy into full Filspari approval decision
- Travere Therapeutics upgraded to Buy from Neutral at Citi
- Travere Therapeutics completes pre-NDA meeting with the FDA for Filspari
